L C Konick1, L Friedman. 1. Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Abstract
BACKGROUND: This article presents a meta-analysis of thalamic size reduction in schizophrenia. METHODS: Reviewed studies were based on magnetic resonance imaging or postmortem material and included measures of thalamic volume or thalamic area in schizophrenic patients and comparison subjects. Meta-analysis I was based on absolute thalamic values (not controlled for overall brain size), and Meta-analysis II evaluated thalamic size adjusted for brain size. RESULTS: Meta-analysis I included data from 15 studies (485 schizophrenic subjects and 500 control subjects). Twelve (80%) of the studies had negative effect sizes, which is consistent with the hypothesis that thalamic size is smaller in schizophrenic subjects compared to control subjects. The composite effect size was -0.29 (p <.0001; without outliers: -0.41, p <.0001). Meta-analysis II included data from 11 studies (313 schizophrenic patients and 434 control subjects). Ten (91%) of the studies had negative effect sizes. The composite effect size was -0.35 (p <.0001; without outlier: -0.30, p <.0001). CONCLUSIONS: Both meta-analyses indicate a statistically significant, small-to-moderate effect size for thalamic size reduction in schizophrenia; however, the effect size for thalamic size reduction is modest in comparison to that of other structural abnormalities noted in schizophrenia.
BACKGROUND: This article presents a meta-analysis of thalamic size reduction in schizophrenia. METHODS: Reviewed studies were based on magnetic resonance imaging or postmortem material and included measures of thalamic volume or thalamic area in schizophrenicpatients and comparison subjects. Meta-analysis I was based on absolute thalamic values (not controlled for overall brain size), and Meta-analysis II evaluated thalamic size adjusted for brain size. RESULTS: Meta-analysis I included data from 15 studies (485 schizophrenic subjects and 500 control subjects). Twelve (80%) of the studies had negative effect sizes, which is consistent with the hypothesis that thalamic size is smaller in schizophrenic subjects compared to control subjects. The composite effect size was -0.29 (p <.0001; without outliers: -0.41, p <.0001). Meta-analysis II included data from 11 studies (313 schizophrenicpatients and 434 control subjects). Ten (91%) of the studies had negative effect sizes. The composite effect size was -0.35 (p <.0001; without outlier: -0.30, p <.0001). CONCLUSIONS: Both meta-analyses indicate a statistically significant, small-to-moderate effect size for thalamic size reduction in schizophrenia; however, the effect size for thalamic size reduction is modest in comparison to that of other structural abnormalities noted in schizophrenia.
Authors: Stefano Marenco; Jason L Stein; Antonina A Savostyanova; Fabio Sambataro; Hao-Yang Tan; Aaron L Goldman; Beth A Verchinski; Alan S Barnett; Dwight Dickinson; José A Apud; Joseph H Callicott; Andreas Meyer-Lindenberg; Daniel R Weinberger Journal: Neuropsychopharmacology Date: 2011-09-28 Impact factor: 7.853
Authors: Päivikki Tanskanen; Khanum Ridler; Graham K Murray; Marianne Haapea; Juha M Veijola; Erika Jääskeläinen; Jouko Miettunen; Peter B Jones; Edward T Bullmore; Matti K Isohanni Journal: Schizophr Bull Date: 2008-11-17 Impact factor: 9.306
Authors: Jessica R Lunsford-Avery; Joseph M Orr; Tina Gupta; Andrea Pelletier-Baldelli; Derek J Dean; Ashley K Smith Watts; Jessica Bernard; Zachary B Millman; Vijay A Mittal Journal: Schizophr Res Date: 2013-10-04 Impact factor: 4.939
Authors: Ian Ellison-Wright; David C Glahn; Angela R Laird; Sarah M Thelen; Ed Bullmore Journal: Am J Psychiatry Date: 2008-04-01 Impact factor: 18.112